AVIGI Therapeutics is developing first-in-class covalent inhibitors targeting heparanase, a key enzyme in extracellular matrix homeostasis, addressing some of the most difficult-to-treat conditions in human health, beginning with cancer and extending to inflammatory diseases and renal disorders.
We use cookies to provide you a better user experience on this website.Privacy & Cookie Policy